中国医药荣获2024年度上市公司“董办优秀实践案例”“董事会优秀实践案例”及“可持续发展优秀实践案例”

Core Viewpoint - China National Pharmaceutical Group (600056.SH) has been awarded the "2024 Annual Excellent Practice Case of the Board Office of Listed Companies" by the China Association of Public Companies, highlighting its effective compliance and communication practices with investors [1] Group 1 - The evaluation aims to enhance the professional capabilities of board office staff in listed companies and establish industry benchmarks [1] - China National Pharmaceutical's recognition reflects its achievements in compliance operations, improving information disclosure quality, and fostering high-quality corporate development [1] - The company also received accolades for its exemplary performance in standardized board operations and sustainable development practices [1]